Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Hepatocellular 222Carcinoma, Renal Cell 84Liver Neoplasms 68Neoplasms 53Leukemia, Myeloid, Acute 37Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 29Melanoma 24Kidney Neoplasms 22Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Thyroid Neoplasms 13Recurrence 13Glioblastoma 13Colorectal Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

Cyclophosphamide 32fludarabine phosphate 30Mycophenolic Acid 24Busulfan 21Antilymphocyte Serum 20Tacrolimus 19Peripheral Blood Stem Cell Transplantation 18Methotrexate 18Melphalan 17Filgrastim 17Whole-Body Irradiation 15Cyclosporine 15thymoglobulin 11fludarabine 11Methylprednisolone 11Cytarabine 11Radiotherapy 10Thiotepa 8Granulocyte Colony-Stimulating Factor 8Cord Blood Stem Cell Transplantation 8Stem Cell Transplantation 7Etoposide 6Clofarabine 6Rituximab 5Azacitidine 5Transplantation 4Sirolimus 4Isotretinoin 4Flow Cytometry 4Antibodies 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Juvenile × Sorafenib × Clear all
NCT01445080 2021-02-02

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 26 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡